FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317387817> ?p ?o ?g. }

• W4317387817 endingPage "8237" @default.
• W4317387817 startingPage "8228" @default.
• W4317387817 abstract "Abstract Background Relapsed or refractory Hodgkin lymphoma (R/R HL) is a challenging disease with limited treatment options beyond brentuximab vedotin and checkpoint inhibitors. Herein we present the time‐trend analysis of R/R HL patients who received allogeneic hematopoietic cell transplantation (allo‐HCT) at our center from 2001–2017. Methods The patients were divided into two distinct treatment cohorts: era1 (2001–2010), and era2 (2011–2017). The primary endpoint was overall survival (OS). Secondary endpoints included progression‐free survival (PFS), non‐relapse mortality (NRM), and cumulative incidence of acute and chronic graft versus host disease (GVHD). Results Among the 51 patients included in the study, 29 were in era1, and 22 were in era2. There was decreased use of myeloablative conditioning in era2 (18% vs. 31%) compared to era1 and 95% of patients in era2 previously received brentuximab Vedotin (BV). Haploidentical donors were seen exclusively in era2 (0% vs. 14%) and more patients received alternative donor transplants (7% vs. 32%) in era2. The 4‐year OS (34% vs. 83%, p < 0.001) and 4‐year PFS (28% vs. 62%, p = 0.001) were significantly inferior in era1 compared to era2. The incidence of 1‐year NRM was lower in era2 compared to era1 (5% vs. 34%, p = 0.06). The cumulative incidence of acute GVHD at day 100 was similar in both eras ( p = 0.50), but the incidence of chronic GVHD at 1 year was higher in era2 compared to era1 (55% vs. 21%, p = 0.03). Conclusions Despite the advent of novel therapies, allo‐HCT remains an important therapeutic option for patients with R/R HL." @default.
• W4317387817 created "2023-01-19" @default.
• W4317387817 creator A5003367392 @default.
• W4317387817 creator A5010473913 @default.
• W4317387817 creator A5012846289 @default.
• W4317387817 creator A5017559837 @default.
• W4317387817 creator A5024389256 @default.
• W4317387817 creator A5036651522 @default.
• W4317387817 creator A5044663373 @default.
• W4317387817 creator A5045749472 @default.
• W4317387817 creator A5051862003 @default.
• W4317387817 creator A5053717205 @default.
• W4317387817 creator A5054730003 @default.
• W4317387817 creator A5058362903 @default.
• W4317387817 creator A5063133761 @default.
• W4317387817 creator A5072835425 @default.
• W4317387817 creator A5081675173 @default.
• W4317387817 creator A5082021894 @default.
• W4317387817 creator A5085565650 @default.
• W4317387817 creator A5085820043 @default.
• W4317387817 creator A5086380393 @default.
• W4317387817 creator A5088169139 @default.
• W4317387817 date "2023-01-18" @default.
• W4317387817 modified "2023-10-03" @default.
• W4317387817 title "Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents" @default.
• W4317387817 cites W1491993932 @default.
• W4317387817 cites W1530764705 @default.
• W4317387817 cites W1794717495 @default.
• W4317387817 cites W1860199933 @default.
• W4317387817 cites W1874317003 @default.
• W4317387817 cites W1945193733 @default.
• W4317387817 cites W1968902284 @default.
• W4317387817 cites W1971984984 @default.
• W4317387817 cites W1980320803 @default.
• W4317387817 cites W2011197626 @default.
• W4317387817 cites W2011644390 @default.
• W4317387817 cites W2020154083 @default.
• W4317387817 cites W2030869855 @default.
• W4317387817 cites W2038308493 @default.
• W4317387817 cites W2044684152 @default.
• W4317387817 cites W2085947607 @default.
• W4317387817 cites W2091865970 @default.
• W4317387817 cites W2109686908 @default.
• W4317387817 cites W2111613096 @default.
• W4317387817 cites W2114043234 @default.
• W4317387817 cites W2118983773 @default.
• W4317387817 cites W2120986426 @default.
• W4317387817 cites W2122654415 @default.
• W4317387817 cites W2124311837 @default.
• W4317387817 cites W2131212219 @default.
• W4317387817 cites W2155256323 @default.
• W4317387817 cites W2169944840 @default.
• W4317387817 cites W2224484444 @default.
• W4317387817 cites W2233814136 @default.
• W4317387817 cites W2500482667 @default.
• W4317387817 cites W2537884769 @default.
• W4317387817 cites W2567998110 @default.
• W4317387817 cites W2594496276 @default.
• W4317387817 cites W2595261904 @default.
• W4317387817 cites W2604605580 @default.
• W4317387817 cites W2611189127 @default.
• W4317387817 cites W2745549673 @default.
• W4317387817 cites W2794872274 @default.
• W4317387817 cites W2891181902 @default.
• W4317387817 cites W2935210822 @default.
• W4317387817 cites W2946038977 @default.
• W4317387817 cites W2968942240 @default.
• W4317387817 cites W2999417355 @default.
• W4317387817 cites W3005305777 @default.
• W4317387817 cites W3016902363 @default.
• W4317387817 cites W3021193152 @default.
• W4317387817 cites W3044350523 @default.
• W4317387817 cites W3133253084 @default.
• W4317387817 cites W3135044089 @default.
• W4317387817 cites W4317387817 @default.
• W4317387817 doi "https://doi.org/10.1002/cam4.5631" @default.
• W4317387817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36653918" @default.
• W4317387817 hasPublicationYear "2023" @default.
• W4317387817 type Work @default.
• W4317387817 citedByCount "3" @default.
• W4317387817 countsByYear W43173878172023 @default.
• W4317387817 crossrefType "journal-article" @default.
• W4317387817 hasAuthorship W4317387817A5003367392 @default.
• W4317387817 hasAuthorship W4317387817A5010473913 @default.
• W4317387817 hasAuthorship W4317387817A5012846289 @default.
• W4317387817 hasAuthorship W4317387817A5017559837 @default.
• W4317387817 hasAuthorship W4317387817A5024389256 @default.
• W4317387817 hasAuthorship W4317387817A5036651522 @default.
• W4317387817 hasAuthorship W4317387817A5044663373 @default.
• W4317387817 hasAuthorship W4317387817A5045749472 @default.
• W4317387817 hasAuthorship W4317387817A5051862003 @default.
• W4317387817 hasAuthorship W4317387817A5053717205 @default.
• W4317387817 hasAuthorship W4317387817A5054730003 @default.
• W4317387817 hasAuthorship W4317387817A5058362903 @default.
• W4317387817 hasAuthorship W4317387817A5063133761 @default.
• W4317387817 hasAuthorship W4317387817A5072835425 @default.
• W4317387817 hasAuthorship W4317387817A5081675173 @default.
• W4317387817 hasAuthorship W4317387817A5082021894 @default.

• next